Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Association of class II and III BRAF mutations with EGFR blockade therapy response and representation of molecularly distinct subgroups of BRAF mutations in MMR proficient CRC.
Authors
Ibrahim Halil Sahin
University of Pittsburgh Medical Center, Pittsburgh, PA
Ibrahim Halil Sahin , Joanne Xiu , Moh'd M. Khushman , Emily Palumbo , Benjamin Adam Weinberg , Mehmet Akce , Aatur D. Singhi , Phoenix D. Bell , Anup Kasi , Anthony F. Shields , Matthew James Oberley , George W. Sledge Jr., John Paul Y.C. Shen , Anwaar Saeed , Mohamedtaki Abdulaziz Tejani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 168)
DOI
10.1200/JCO.2024.42.3_suppl.168
Abstract #
168
Poster Bd #
K16
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Identification of novel and potentially targetable receptor tyrosine kinase alterations in colorectal carcinoma using a 341 gene hybrid capture-based next-generation sequencing assay.
First Author: Jaclyn Frances Hechtman
Poster
2024 ASCO Gastrointestinal Cancers Symposium
High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness.
First Author: Ramya Thota
First Author: Sandra Algaze
Poster
2017 Gastrointestinal Cancers Symposium
Blood-based genomic profiling of circulating cell-free tumor DNA (ctDNA) in 1397 patients (pts) with colorectal cancer (CRC).
First Author: John H. Strickler